With help from Pillsbury, medical genetics company Invitae closed a $184 million deal for its underwritten public offering of shares of common stock.

The offering comprised over 20 million shares of Invitae common stock. Among the securities offered were over two million shares of Invitae common stock sold as the underwriting syndicate exercised its allotment option. Invitae sold all shares in the offering without help from selling stockholders.

Invitae stock now trades on The New York Stock Exchange under the symbol “NVTA.”

The Pillsbury team was led by Silicon Valley Corporate partner Gabriella Lombardi and included senior associate Julie Park with support from Charmaine Lindley and Jasmine Alves. The team was assisted by Corporate partners Mike Hird and Richard Blaylock in San Diego. Additionally, partner Harsha Reddy advised on tax matters from New York.